← Eichor
Study identifier: NCT06488482 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma

Condition: High-risk Melanoma  ·  Sponsor: Uppsala University

PhasePhase 3
Planned participants1792
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

1. Rational Every year, around 5,000 people in Sweden are diagnosed with malignant skin melanoma. In the early stages of malignant skin melanoma, the chance of cure with surgery is very good. At a later stage, when the melanoma has become thick and/or has spread, the risk of recurrence is greater despite radical surgery. Therefore, in these cases (even in cases of recurrence after radical surgery), additional treatment with immunotherapy is often given, as it has been shown to reduce the risk of recurrence. Immunotherapy is given for one year based on previous research studies, but it has not been investigated whether a shorter treatment period has the same effect. The hypothesis is that six months of treatment is equally effective, which would have several advantages. The main advantage of a shorter treatment period is that the risk of severe side effects is reduced. A shorter treatment period also means fewer hospital visits for patients. In addition, significant drug costs and other healthcare resources could be saved. 2. Aim/objective The aim of the study is to investigate whether 6 months of treatment with immunotherapy, in addition to radical surgery, for malignant skin melanoma at high risk of recurrence, is as effective in preventing recurrence as 12 months of treatment. Secondary objectives: To investigate overall survival after 6 versus 12 months of treatment with immunotherapy. To investigate the health economic effects of a shorter treatment. 3. Primar…

This description comes directly from the study's public registry record.

Talk to the study team

Gustav J Ullenhag, professor  ·  +46-18-6110000  ·  Gustav.Ullenhag@IGP.uu.se

Leila Boukharta, MSc  ·  +46-18-6110000  ·  Leila.Boukharta@Akademiska.se

Always discuss trial participation with your own doctor first.

Locations (26)

Helsinki University HospitalHelsinki, FinlandRecruiting
Kuopio University HospitalKuopio, FinlandRecruiting
Tampere University HospitalTampere, FinlandRecruiting
Turku University HospitalTurku, FinlandRecruiting
Ålesund HospitalÅlesund, NorwayRecruiting
Haukeland University HospitalBergen, NorwayRecruiting
Sorlandet HospitalKristiansand, NorwayRecruiting
Akershus University HospitalOslo, NorwayRecruiting
Oslo University HospitalOslo, NorwayRecruiting
Stavanger University HospitalStavanger, NorwayRecruiting
North Norway University HospitalTromsø, NorwayRecruiting
Trondheim University HospitalTrondheim, NorwayRecruiting

+ 14 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06488482